Gene · 8764
Papers3,537
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
1,121 to 1,140 of 3,537
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Single-Cell Transcriptome Analysis Reveals Changes of Tumor Immune Microenvironment in Oral Squamous Cell Carcinoma After Chemotherapy. | Front Cell Dev Biol | 2022 | 35784460 | PubTator, text mining | PubMed |
| Characterization of Ligand-Receptor Pair in Bladder Cancer Develops a Validated Scoring Model for Prognosis and Treatment Response. | Front Cell Dev Biol | 2022 | 35784457 | PubTator, text mining | PubMed |
| Nanobody-based retargeting of an oncolytic herpesvirus for eliminating CXCR4+ GBM cells: A proof of principle. | Mol Ther Oncolytics | 2022 | 35784400 | PubTator, text mining | PubMed |
| Comprehensive Urinomic Identification of Protein Alternatives to Creatinine Normalization for Diagnostic Assessment of Lupus Nephritis. | Front Immunol | 2022 | 35774777 | PubTator, text mining | PubMed |
| Prediction of Prognosis and Molecular Mechanism of Ferroptosis in Hepatocellular Carcinoma Based on Bioinformatics Methods. | Comput Math Methods Med | 2022 | 35774297 | PubTator, text mining | PubMed |
| Role of GBP1 in innate immunity and potential as a tuberculosis biomarker. | Sci Rep | 2022 | 35773466 | PubTator, text mining | PubMed |
| Identification of m7G-associated lncRNA prognostic signature for predicting the immune status in cutaneous melanoma. | Aging (Albany NY) | 2022 | 35771136 | PubTator, text mining | PubMed |
| Immunological Characteristics of Alternative Splicing Profiles Related to Prognosis in Bladder Cancer. | Front Immunol | 2022 | 35769470 | PubTator, text mining | PubMed |
| A Whole Exon Screening-Based Score Model Predicts Prognosis and Immune Checkpoint Inhibitor Therapy Effects in Low-Grade Glioma. | Front Immunol | 2022 | 35769464 | PubTator, text mining | PubMed |
| Peripheral blood CD3+ T-cell gene expression biomarkers correlate with clinical frailty in patients with haematological malignancies. | Br J Haematol | 2022 | 35766906 | PubTator, text mining | PubMed |
| Neurexophilin 4 is a prognostic biomarker correlated with immune infiltration in bladder cancer. | Bioengineered | 2022 | 35758021 | PubTator, text mining | PubMed |
| Hepatic Stellate Cell-Immune Interactions in NASH. | Front Endocrinol (Lausanne) | 2022 | 35757404 | PubTator, text mining | PubMed |
| MAIP1-Related Tumor Immune Infiltration: As a Potential Prognostic Biomarker for Esophageal Cancer. | J Immunol Res | 2022 | 35747687 | PubTator, text mining | PubMed |
| Differential Immune Checkpoint and Ig-like V-Type Receptor Profiles in COVID-19: Associations with Severity and Treatment. | J Clin Med | 2022 | 35743356 | PubTator, text mining | PubMed |
| Incidence and Risk Factors of Bilateral Herpetic Keratitis: 2022 Update. | Trop Med Infect Dis | 2022 | 35736971 | PubTator, text mining | PubMed |
| Recent Advances in the Recognition Elements of Sensors to Detect Pyrethroids in Food: A Review. | Biosensors (Basel) | 2022 | 35735550 | PubTator, text mining | PubMed |
| m6A-Regulator Expression Signatures Identify a Subset of Follicular Lymphoma Harboring an Exhausted Tumor Microenvironment. | Front Immunol | 2022 | 35734168 | PubTator, text mining | PubMed |
| FCGBP Is a Promising Prognostic Biomarker and Correlates with Immunotherapy Efficacy in Oral Squamous Cell Carcinoma. | J Immunol Res | 2022 | 35733916 | PubTator, text mining | PubMed |
| The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. | Leukemia | 2022 | 35732829 | PubTator, text mining | PubMed |
| Dynamic Immune Landscape and VZV-Specific T Cell Responses in Patients With Herpes Zoster and Postherpetic Neuralgia. | Front Immunol | 2022 | 35720399 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/8764/papers?page=57